Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileJason Alexander Efstathiou, M.D., PH.D.

TitleAssociate Professor of Radiation Oncology
InstitutionMassachusetts General Hospital
DepartmentRadiation Oncology
AddressMassachusetts General Hospital
Radiation Oncology, Cox-3
100 Blossom Street
Boston MA 02114
Phone617/726-5866
Fax617/736-3603
vCardDownload vCard (login for email)

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL. Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Med. 2017 May 31. PMID: 28560840.
    View in: PubMed
  2. Xiang HF, Lu HM, Efstathiou JA, Zietman AL, Armas R, Harris K, Bloch BN, Qureshi MM, Keohan S, Hirsch AE. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys. 2017 May; 18(3):37-43. PMID: 28407345.
    View in: PubMed
  3. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. J Clin Oncol. 2017 May 20; 35(15):1737-1743. PMID: 28346805.
    View in: PubMed
  4. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations. Phys Med Biol. 2017 Mar 07; 62(5):1644-1660. PMID: 28166057.
    View in: PubMed
  5. Baumann BC, Sargos P, Eapen LJ, Efstathiou JA, Choudhury A, Bahl A, Murthy V, Ballas LK, Fonteyne V, Richaud PM, Zaghloul MS, Christodouleas JP. The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer. 2017 Jan 27; 3(1):19-30. PMID: 28149931.
    View in: PubMed
  6. Underwood TS, Voog JC, Moteabbed M, Tang S, Soffen E, Cahlon O, Lu HM, Zietman AL, Efstathiou JA, Paganetti H. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol. 2017 Apr; 56(4):575-581. PMID: 28075206.
    View in: PubMed
  7. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 Jun; 71(6):952-960. PMID: 28081860.
    View in: PubMed
  8. Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2016 Dec 28. PMID: 28040351.
    View in: PubMed
  9. Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 Mar 01; 97(3):450-461. PMID: 28011046.
    View in: PubMed
  10. Buscariollo DL, Drumm M, Niemierko A, Clayman RH, Galland-Girodet S, Rodin D, Feldman AS, M Dahl D, McGovern FJ, F Olumi A, Eidelman A, Shipley WU, Zietman AL, Efstathiou JA. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e125-e133. PMID: 28274403.
    View in: PubMed
  11. Efstathiou JA. Introduction. Semin Radiat Oncol. 2017 Jan; 27(1):1-2. PMID: 27986206.
    View in: PubMed
  12. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct; 14(10):1213-1224. PMID: 27697976.
    View in: PubMed
  13. Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, Orré M, Efstathiou JA, Shariat S, Larré S, Richaud P, Christodouleas JP. Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider? Transl Androl Urol. 2016 Oct; 5(5):702-710. PMID: 27785427.
    View in: PubMed
  14. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 Dec 01; 96(5):1046-1053. PMID: 27745980.
    View in: PubMed
  15. Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol. 2017 May; 71(5):729-737. PMID: 27597241.
    View in: PubMed
  16. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, Grover S, Chiyapo S, Ramogola-Masire D, Kebabonye-Pusoentsi M, Clayman R, Mapes AC, Tapela N, Asmelash A, Medhin H, Viswanathan AN, Russell AH, Lin LL, Kayembe MK, Mmalane M, Randall TC, Chabner B, Lockman S. HIV Infection and Survival Among Women With Cervical Cancer. J Clin Oncol. 2016 Aug 29. PMID: 27573661.
    View in: PubMed
  17. Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 Dec 01; 96(5):1028-1036. PMID: 27727064.
    View in: PubMed
  18. Roberts HJ, Zietman AL, Efstathiou JA. Painting Dose: The ART of Radiation. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4):722-728. PMID: 27788945.
    View in: PubMed
  19. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Aug 15. PMID: 27528718.
    View in: PubMed
  20. Gakis G, Efstathiou JA, Daneshmand S, Keegan KA, Clayman RH, Hrbacek J, Ali-El-Dein B, Zaid HB, Schubert T, Mischinger J, Todenhöfer T, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Morgan TM. Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. Urol Int. 2016; 97(2):134-41. PMID: 27462702.
    View in: PubMed
  21. Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urol Oncol. 2017 Feb; 35(2):59-68. PMID: 27395453.
    View in: PubMed
  22. Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut MH, Hamstra DA, Roof KS, Jeffrey Lee R, Gore EM, Sandler HM, Shipley WU. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016 Oct; 34(10):430.e1-7. PMID: 27381895; PMCID: PMC5035191 [Available on 10/01/17].
  23. Benedict SH, Hoffman K, Martel MK, Abernethy AP, Asher AL, Capala J, Chen RC, Chera B, Couch J, Deye J, Efstathiou JA, Ford E, Fraass BA, Gabriel PE, Huser V, Kavanagh BD, Khuntia D, Marks LB, Mayo C, McNutt T, Miller RS, Moore KL, Prior F, Roelofs E, Rosenstein BS, Sloan J, Theriault A, Vikram B. Overview of the American Society for Radiation Oncology-National Institutes of Health-American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. Int J Radiat Oncol Biol Phys. 2016 Jul 01; 95(3):873-879. PMID: 27302503; PMCID: PMC4965164.
  24. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810. PMID: 27345655.
    View in: PubMed
  25. Makufa R, Bvochora-Nsingo M, Karumekayi T, Schneider RJ, Efstathiou JA, Dryden-Peterson S, Odom A, Shulman A, Pipman Y, Gierga DP. SU-F-P-09: A Global Medical Physics Collaboration for Implementation of Modern Radiotherapy in Botswana. Med Phys. 2016 Jun; 43(6):3359-3360. PMID: 28047638.
    View in: PubMed
  26. Moteabbed M, Trofimov A, Sharp G, Wang Y, Zietman A, Efstathiou J, Lu H. SU-G-JeP4-09: Impact of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy for Prostate Cancer. Med Phys. 2016 Jun; 43(6):3683. PMID: 28046335.
    View in: PubMed
  27. Paly JJ, Lin CC, Gray PJ, Hallemeier CL, Beard C, Sineshaw H, Jemal A, Efstathiou JA. Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e249-e258. PMID: 27345128.
    View in: PubMed
  28. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016 Sep 01; 96(1):78-86. PMID: 27511849.
    View in: PubMed
  29. Hedgire S, Tonyushkin A, Kilcoyne A, Efstathiou JA, Hahn PF, Harisinghani M. Quantitative study of prostate cancer using three dimensional fiber tractography. World J Radiol. 2016 Apr 28; 8(4):397-402. PMID: 27158426; PMCID: PMC4840197.
  30. Shah A, Ricci KI, Efstathiou JA. Beyond a moonshot: insurance coverage for proton therapy. Lancet Oncol. 2016 May; 17(5):559-61. PMID: 27301029.
    View in: PubMed
  31. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138.
    View in: PubMed
  32. Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE. Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer. 2016 Apr 27; 2(2):203-213. PMID: 27376139.
    View in: PubMed
  33. Brown CA, Suneja G, Tapela N, Mapes A, Pusoentsi M, Mmalane M, Hodgeman R, Boyer M, Musimar Z, Ramogola-Masire D, Grover S, Nsingo-Bvochora M, Kayembe M, Efstathiou J, Lockman S, Dryden-Peterson S. Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist. 2016 Jun; 21(6):731-8. PMID: 27053501; PMCID: PMC4912361 [Available on 12/01/16].
  34. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. PMID: 26970022.
    View in: PubMed
  35. Voog JC, Smith MR, Efstathiou JA. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2016 Mar 08; 315(10):1054-5. PMID: 26954419.
    View in: PubMed
  36. Gray PJ, Efstathiou JA, Shipley WU. Words of Wisdom. Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study. Eur Urol. 2016 Apr; 69(4):757-8. PMID: 26972501.
    View in: PubMed
  37. Liu Q, Underwood TS, Kung J, Wang M, Lu HM, Paganetti H, Held KD, Hong TS, Efstathiou JA, Willers H. Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):78-85. PMID: 27084631; PMCID: PMC4889010 [Available on 05/01/17].
  38. Underwood T, Giantsoudi D, Moteabbed M, Zietman A, Efstathiou J, Paganetti H, Lu HM. Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):454-64. PMID: 27084660.
    View in: PubMed
  39. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):444-53. PMID: 26907917; PMCID: PMC4834287 [Available on 05/01/17].
  40. Elmore SN, Sethi RV, Viswanathan AN, Efstathiou JA. Global Radiation Oncology From the Trainee Perspective: A View From Beyond the Bunker. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):438-9. PMID: 26867872.
    View in: PubMed
  41. Efstathiou JA, Heunis M, Karumekayi T, Makufa R, Bvochora-Nsingo M, Gierga DP, Suneja G, Grover S, Kasese J, Mmalane M, Moffat H, von Paleske A, Makhema J, Dryden-Peterson S. Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana. J Clin Oncol. 2016 Jan 01; 34(1):27-35. PMID: 26578607.
    View in: PubMed
  42. Rosenstein BS, Capala J, Efstathiou JA, Hammerbacher J, Kerns SL, Kong FS, Ostrer H, Prior FW, Vikram B, Wong J, Xiao Y. How Will Big Data Improve Clinical and Basic Research in Radiation Therapy? Int J Radiat Oncol Biol Phys. 2016 Jul 01; 95(3):895-904. PMID: 26797542; PMCID: PMC4864183 [Available on 07/01/17].
  43. Voog JC, Efstathiou JA. Treatment Trends for Prostate Cancer. JAMA. 2015 Nov 10; 314(18):1976-7. PMID: 26547472.
    View in: PubMed
  44. Ngwa W, Ngoma T, Zietman A, Mayr N, Elzawawy A, Winningham TA, Balogun O, Enwerem-Bromson N, Ntizimira C, Olopade OI, Oluwole D, Odedina F, Williams M, Flanigan J, Asana L, Ngwa K, Avery S, Pollard JM, Roland T, Funwi-gabga N, Mbarika V, Hardenbergh P, Winkfield K, Pipman Y, Stefan C, Ngoma M, Mohammed S, Katz M, Erno S, Moni J, Fitzgerald T, Tonlaar N, Efstathiou J, Gierga D, Ayo C, Knaul F, Gospodarowicz M, Makrigiorgos GM, Nguyen PL. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9. PMID: 26867873; PMCID: PMC4959435.
  45. Grover S, Raesima M, Bvochora-Nsingo M, Chiyapo SP, Balang D, Tapela N, Balogun O, Kayembe MK, Russell AH, Monare B, Tanyala S, Bhat J, Thipe K, Nchunga M, Mayisela S, Kizito B, Ho-Foster A, Gaolebale BE, Gaolebale PA, Efstathiou JA, Dryden-Peterson S, Zetola N, Hahn SM, Robertson ES, Lin LL, Morroni C, Ramogola-Masire D. Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. Front Oncol. 2015; 5:239. PMID: 26579491; PMCID: PMC4630577.
  46. Voog JC, Paulus R, Efstathiou JA. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy. Eur Urol. 2016 Feb; 69(2):212-3. PMID: 26443430; PMCID: PMC4893789.
  47. Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2016 Jan 01; 122(1):78-83. PMID: 26371600.
    View in: PubMed
  48. Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol. 2016 Feb; 69(2):204-10. PMID: 26362090; PMCID: PMC4784682 [Available on 02/01/17].
  49. Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85. PMID: 26235660.
    View in: PubMed
  50. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Response. J Natl Cancer Inst. 2015 Sep; 107(9). PMID: 26209711; PMCID: PMC4836805.
  51. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu H. SU-E-T-457: Impact of Interfractional Variations On Anterior Vs. Lateral-Field Proton Therapy of Prostate Cancer. Med Phys. 2015 Jun; 42(6):3439. PMID: 26128119.
    View in: PubMed
  52. Underwood T, Giantsoudi D, Moteabbed M, Zietman A, Efstathiou J, Paganetti H, Lu HM. TU-EF-304-05: Anterior Proton Beams for Prostate Treatments Lead to Substantial Elevations in Modeled RBE-Weighted Rectal Dose. Med Phys. 2015 Jun; 42(6):3615. PMID: 26128957.
    View in: PubMed
  53. Gakis G, Morgan TM, Efstathiou JA, Keegan KA, Mischinger J, Todenhoefer T, Schubert T, Zaid HB, Hrbacek J, Ali-El-Dein B, Clayman RH, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Daneshmand S. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol. 2016 Jan; 34(1):97-103. PMID: 25981402.
    View in: PubMed
  54. Willers H, Gheorghiu L, Liu Q, Efstathiou JA, Wirth LJ, Krause M, von Neubeck C. DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol. 2015 Oct; 25(4):237-50. PMID: 26384272; PMCID: PMC4575410 [Available on 10/01/16].
  55. Gakis G, Morgan TM, Daneshmand S, Keegan KA, Todenhöfer T, Mischinger J, Schubert T, Zaid HB, Hrbacek J, Ali-El-Dein B, Clayman RH, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Efstathiou JA. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol. 2015 Aug; 26(8):1754-9. PMID: 25969370.
    View in: PubMed
  56. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25957435.
    View in: PubMed
  57. Buchwald ZS, Efstathiou JA. Words of wisdom. Re: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Eur Urol. 2015 May; 67(5):975. PMID: 25845961.
    View in: PubMed
  58. Sineshaw HM, Gray PJ, Efstathiou JA, Jemal A. Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. Eur Urol. 2015 Nov; 68(5):768-74. PMID: 25896124.
    View in: PubMed
  59. Liu Q, Ghosh P, Magpayo N, Testa M, Tang S, Gheorghiu L, Biggs P, Paganetti H, Efstathiou JA, Lu HM, Held KD, Willers H. Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation. Int J Radiat Oncol Biol Phys. 2015 Apr 01; 91(5):1081-9. PMID: 25832698.
    View in: PubMed
  60. Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015 04; 12(4):225-35. PMID: 25800393.
    View in: PubMed
  61. Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H. Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res. 2015 Apr; 13(4):713-20. PMID: 25667133; PMCID: PMC4410013.
  62. Moteabbed M, Sharp GC, Wang Y, Trofimov A, Efstathiou JA, Lu HM. Validation of a deformable image registration technique for cone beam CT-based dose verification. Med Phys. 2015 Jan; 42(1):196-205. PMID: 25563260; PMCID: PMC4277556 [Available on 01/01/16].
  63. Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015 Jan; 13(1):61-8. PMID: 25583770.
    View in: PubMed
  64. Jani AB, Efstathiou JA, Shipley WU. Bladder preservation strategies. Hematol Oncol Clin North Am. 2015 Apr; 29(2):289-300, ix. PMID: 25836935.
    View in: PubMed
  65. Mahal BA, Hoffman KE, Efstathiou JA, Nguyen PL. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer. 2015 Jun; 13(3):e167-72. PMID: 25554010.
    View in: PubMed
  66. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 01; 32(34):3801-9. PMID: 25366678; PMCID: PMC4239302 [Available on 12/01/15].
  67. Gray PJ, Lin CC, Sineshaw H, Paly JJ, Jemal A, Efstathiou JA. Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility. Cancer. 2015 Mar 01; 121(5):681-7. PMID: 25345675.
    View in: PubMed
  68. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2015 Feb; 33(2):53-64. PMID: 25065704.
    View in: PubMed
  69. Efstathiou JA, Bvochora-Nsingo M, Gierga DP, Alphonse Kayembe MK, Mmalane M, Russell AH, Paly JJ, Brown C, Musimar Z, Abramson JS, Bruce KA, Karumekayi T, Clayman R, Hodgeman R, Kasese J, Makufa R, Bigger E, Suneja G, Busse PM, Randall TC, Chabner BA, Dryden-Peterson S. Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):468-75. PMID: 24929156.
    View in: PubMed
  70. Bvochara-Nsingo M, Grover S, Gierga DP, Makufa R, Efstathiou JA, Dixit N, Clayman RH, Russell AH, Lin LL, Kasese J. Cervical brachytherapy exchange: steps toward oncology capacity building in Botswana. Oncologist. 2014 Jul; 19(7):e1-2. PMID: 24928614; PMCID: PMC4077441.
  71. Moteabbed M, Trofimov A, Testa M, Sharp G, Wang Y, Paganetti H, Zietman A, Efstathiou J, Lu H. SU-E-T-616: Comparison of Plan Dose Accuracy for Anterior Vs. Lateral Fields in Proton Therapy of Prostate Cancer. Med Phys. 2014 Jun; 41(6):369. PMID: 28037706.
    View in: PubMed
  72. Xiang H, Qureshi M, De Armas R, Hirsch A, Katz M, Nicholas B, Keohan S, Lu H, Efstathiou J, Zietman A, Willins J, Kachnic J. SU-E-J-150: Impact of Intrafractional Prostate Motion On the Accuracy and Efficiency of Prostate SBRT Delivery: A Retrospective Analysis of Prostate Tracking Log Files. Med Phys. 2014 Jun; 41(6):190-191. PMID: 28036665.
    View in: PubMed
  73. Ramogola-Masire D, Russell AH, Dryden-Peterson S, Efstathiou JA, Kayembe MK, Wilbur DC. Case records of the Massachusetts General Hospital. Case 16-2014. A 46-year-old woman in Botswana with postcoital bleeding. N Engl J Med. 2014 May 22; 370(21):2032-41. PMID: 24849087.
    View in: PubMed
  74. Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21. PMID: 24726149.
    View in: PubMed
  75. Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1048-56. PMID: 24661658.
    View in: PubMed
  76. Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res. 2014 May 15; 74(10):2825-34. PMID: 24648348; PMCID: PMC4278592.
  77. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014 Jul; 66(1):120-37. PMID: 24613684.
    View in: PubMed
  78. McDougal WS, Lee RJ, Efstathiou JA, Harisinghani M, Wu CL. Case records of the Massachusetts General Hospital. Case 2-2014. A 44-year-old man with a lesion on the penis. N Engl J Med. 2014 Jan 16; 370(3):263-71. PMID: 24428472.
    View in: PubMed
  79. Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martínez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley WU, Zietman AL, Efstathiou JA. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):618-23. PMID: 24411190.
    View in: PubMed
  80. Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014 Mar; 10(2):107-12. PMID: 24399853.
    View in: PubMed
  81. Yu JB, Efstathiou JA, Bekelman JE. Proton radiotherapy for prostate cancer: how did we get here, and where do we go from here? Oncology (Williston Park). 2013 Dec; 27(12):1293-4. PMID: 24624550.
    View in: PubMed
  82. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72. PMID: 24225970.
    View in: PubMed
  83. Gray PJ, Shipley WU, Efstathiou JA. T1 high-grade bladder cancer recurring after BCG therapy: a curative alternative to radical cystectomy exists. Con. Oncology (Williston Park). 2013 Sep; 27(9):873, 921. PMID: 24282983.
    View in: PubMed
  84. Gray PJ, Shipley WU, Efstathiou JA, Zietman AL. Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer. Curr Opin Urol. 2013 Sep; 23(5):429-34. PMID: 23851382.
    View in: PubMed
  85. Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013 Aug; 11(8):952-60. PMID: 23946174.
    View in: PubMed
  86. Mitin T, Blute M, Lee R, Efstathiou J. Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy. Oncology (Williston Park). 2013 Jul; 27(7):647-55. PMID: 23977759.
    View in: PubMed
  87. Wang Y, Efstathiou JA, Lu HM, Sharp GC, Trofimov A. Hypofractionated proton therapy for prostate cancer: dose delivery uncertainty due to interfractional motion. Med Phys. 2013 Jul; 40(7):071714. PMID: 23822418; PMCID: PMC3695961.
  88. Aizer AA, Paly JJ, Efstathiou JA. Multidisciplinary care and management selection in prostate cancer. Semin Radiat Oncol. 2013 Jul; 23(3):157-64. PMID: 23763881.
    View in: PubMed
  89. Gray PJ, Efstathiou JA. Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified? Curr Urol Rep. 2013 Jun; 14(3):199-208. PMID: 23546839.
    View in: PubMed
  90. Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A. Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. Oncologist. 2013 Jun; 18(6):685-6. PMID: 23728940; PMCID: PMC4063394.
  91. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract. 2013 May; 9(3):e90-5. PMID: 23942508; PMCID: PMC3651578.
  92. Hayman JA, Bosserman LD, Efstathiou JA. Summary of oral abstract session B: innovating to improve care quality. J Oncol Pract. 2013 May; 9(3):158-9. PMID: 23942498; PMCID: PMC3651567.
  93. Zeng C, Giantsoudi D, Grassberger C, Goldberg S, Niemierko A, Paganetti H, Efstathiou JA, Trofimov A. Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions. Med Phys. 2013 May; 40(5):051708. PMID: 23635256; PMCID: PMC3651218.
  94. Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Curr Urol Rep. 2013 Apr; 14(2):109-15. PMID: 23341373.
    View in: PubMed
  95. Mouw KW, Trofimov A, Zietman AL, Efstathiou JA. Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol. 2013 Apr; 23(2):109-14. PMID: 23473687; PMCID: PMC3595123.
  96. Wala J, Craft D, Paly J, Zietman A, Efstathiou J. Maximizing dosimetric benefits of IMRT in the treatment of localized prostate cancer through multicriteria optimization planning. Med Dosim. 2013; 38(3):298-303. PMID: 23540492.
    View in: PubMed
  97. Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Zietman AL, Beard C. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Pract Radiat Oncol. 2013 Apr-Jun; 3(2 Suppl 1):S30. PMID: 24674542.
    View in: PubMed
  98. Efstathiou JA, Gray PJ, Zietman AL. Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer. 2013 Apr 02; 108(6):1225-30. PMID: 23481182; PMCID: PMC3619274.
  99. Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):311-6. PMID: 23474117.
    View in: PubMed
  100. Gray PJ, Efstathiou JA, Shipley WU. The opportunity cost of androgen suppression in locally advanced prostate cancer. Asian J Androl. 2013 May; 15(3):356-7. PMID: 23435474; PMCID: PMC3739662.
  101. Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35. PMID: 23436283; PMCID: PMC3759976.
  102. Paly JJ, Zietman AL, Nguyen PL, Beard C, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55. PMID: 28137047.
    View in: PubMed
  103. Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martinez-Monge R, Whitson JM, Calvo FA, Fastner G, Wong W, Ellis RJ, Efstathiou JA. Outcomes for a multi-institutional cohort of patients treated with intra-operative radiation therapy for advanced or recurrent renal cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):442. PMID: 28136946.
    View in: PubMed
  104. Fedewa SA, Shipley WU, Lin CC, Virgo KS, Kibel AS, Kamat AM, Rosenberg JE, Jemal A, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. J Clin Oncol. 2013 Feb 20; 31(6_suppl):248. PMID: 28136792.
    View in: PubMed
  105. Gray PJ, Efstathiou JA. Prostate cancer: Proton therapy--revolutionary advance or diminishing returns? Nat Rev Urol. 2013 Mar; 10(3):128-9. PMID: 23399730.
    View in: PubMed
  106. Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol. 2013 Jan; 106(1):64-8. PMID: 23321493.
    View in: PubMed
  107. Chabner BA, Efstathiou J, Dryden-Peterson S. Cancer in Botswana: the second wave of AIDS in Sub-Saharan Africa. Oncologist. 2013; 18(7):777-8. PMID: 23882018; PMCID: PMC3720627.
  108. Efstathiou JA, Shipley WU. Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2013 Jan; 63(1):181-2. PMID: 23218494.
    View in: PubMed
  109. Shah A, Paly JJ, Efstathiou JA, Bekelman JE. Physician evaluation of internet health information on proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):e173-7. PMID: 23245278; PMCID: PMC4277870.
  110. Mitin T, Efstathiou JA, Shipley WU. Urological cancer. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol. 2012 Dec; 9(12):672-3. PMID: 23165125.
    View in: PubMed
  111. Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013 May; 63(5):823-9. PMID: 23200811.
    View in: PubMed
  112. Efstathiou JA. Postoperative radiation for prostate cancer. Lancet. 2012 Dec 08; 380(9858):1974-6. PMID: 23084480.
    View in: PubMed
  113. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57. PMID: 22917985.
    View in: PubMed
  114. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6. PMID: 22851571.
    View in: PubMed
  115. Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e445-52. PMID: 22436787.
    View in: PubMed
  116. Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):782-90. PMID: 22425219; PMCID: PMC3361528.
  117. Efstathiou JA, Paly JJ, Lu HM, Athar BS, Moteabbed M, Niemierko A, Adams JA, Bekelman JE, Shipley WU, Zietman AL, Paganetti H. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol. 2012 Apr; 103(1):12-7. PMID: 22391053.
    View in: PubMed
  118. Shah A, Efstathiou JA, Paly JJ, Halpern SD, Bruner DW, Christodouleas JP, Coen JJ, Deville C, Vapiwala N, Shipley WU, Zietman AL, Hahn SM, Bekelman JE. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):e13-9. PMID: 22381899.
    View in: PubMed
  119. Paly JJ, Efstathiou JA, Hedgire S, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Zietman AL, Shipley WU, Beard C. Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields. J Clin Oncol. 2012 Feb 10; 30(5_suppl):324. PMID: 28143011.
    View in: PubMed
  120. Katz LM, Efstathiou JA, Opraseuth J, Killoran J, Paly JJ, Weathers R, Stovall M, Beard C. Normal tissue exposure during retroperitoneal radiotherapy for pure seminoma of the testis. J Clin Oncol. 2012 Feb 10; 30(5_suppl):334. PMID: 28142971.
    View in: PubMed
  121. Aizer A, Paly JJ, Zietman AL, D'Amico AV, Nguyen PL, Beard C, Rao SK, Kaplan ID, Hirsch MS, Wu CL, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131. PMID: 28143227.
    View in: PubMed
  122. Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Virgo KS, Zietman AL. Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base. J Clin Oncol. 2012 Feb 10; 30(5_suppl):272. PMID: 28143299.
    View in: PubMed
  123. Gray PJ, Paly JJ, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen J, Shipley WU, Zietman AL, Bekelman JE, Efstathiou JA. Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):22. PMID: 28142916.
    View in: PubMed
  124. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2012 Feb 10; 30(5_suppl):264. PMID: 28143313.
    View in: PubMed
  125. Efstathiou JA, Paulus R, Smith MR, Jones CU, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. J Clin Oncol. 2012 Feb 10; 30(5_suppl):18. PMID: 28142889.
    View in: PubMed
  126. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9. PMID: 22302227; PMCID: PMC3286170.
  127. Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, McGovern F, Shipley WU. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012 Feb; 187(2):463-8. PMID: 22177159.
    View in: PubMed
  128. Tang S, Both S, Bentefour H, Paly JJ, Tochner Z, Efstathiou J, Lu HM. Improvement of prostate treatment by anterior proton fields. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):408-18. PMID: 22133626.
    View in: PubMed
  129. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012 Apr; 61(4):705-11. PMID: 22101114.
    View in: PubMed
  130. Wang Y, Efstathiou JA, Sharp GC, Lu HM, Ciernik IF, Trofimov AV. Evaluation of the dosimetric impact of interfractional anatomical variations on prostate proton therapy using daily in-room CT images. Med Phys. 2011 Aug; 38(8):4623-33. PMID: 21928635; PMCID: PMC3161503.
  131. Wang Y, Efstathiou JA, Sharp GC, Lu HM, Frank Ciernik I, Trofimov AV. Evaluation of the dosimetric impact of interfractional anatomical variations on prostate proton therapy using daily in-room CT images. Med Phys. 2011 Aug; 38(8):4623-4633. PMID: 28525162.
    View in: PubMed
  132. Palta JR, Efstathiou JA, Bekelman JE, Mutic S, Bogardus CR, McNutt TR, Gabriel PE, Lawton CA, Zietman AL, Rose CM. Developing a national radiation oncology registry: From acorns to oaks. Pract Radiat Oncol. 2012 Jan-Mar; 2(1):10-7. PMID: 24674031.
    View in: PubMed
  133. Lee WR, Dignam J, Bruner D, Efstathiou JA, Yan Y, Hanks GE, Roach M, Pilepich MV, Sandler HM. Does enrollment setting influence patient attributes and outcomes in RTOG prostate cancer trials? J Clin Oncol. 2011 May 20; 29(15_suppl):4607. PMID: 28024019.
    View in: PubMed
  134. Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, Armstrong K. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e325-34. PMID: 21498008; PMCID: PMC4265571.
  135. Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, Shipley WU. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e25-31. PMID: 21470787.
    View in: PubMed
  136. Trofimov A, Nguyen PL, Efstathiou JA, Wang Y, Lu HM, Engelsman M, Merrick S, Cheng CW, Wong JR, Zietman AL. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):928-37. PMID: 20947266; PMCID: PMC3026870.
  137. Igdem S, Spiegel DY, Efstathiou J, Miller RC, Poortmans PM, Koca S, Kiliç-Unsal D, Okkan S, Zietman A. Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes - a Rare Cancer Network study. Onkologie. 2010; 33(4):169-73. PMID: 20389142.
    View in: PubMed
  138. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22. PMID: 20346051; PMCID: PMC3090683.
  139. Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1081-5. PMID: 20207497.
    View in: PubMed
  140. Efstathiou JA, Shipley WU, Zietman AL, Smith MR. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol. 2010 Mar; 7(3):130-2. PMID: 20190794; PMCID: PMC2900769.
  141. Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5. PMID: 19957321.
    View in: PubMed
  142. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010 Mar 01; 28(7):1106-11. PMID: 20124169; PMCID: PMC2834463.
  143. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009 Sep 01; 27(25):4055-61. PMID: 19636019; PMCID: PMC2734419.
  144. Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. Cancer J. 2009 Jul-Aug; 15(4):312-8. PMID: 19672148.
    View in: PubMed
  145. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 01; 27(1):92-9. PMID: 19047297; PMCID: PMC2645096.
  146. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008 Sep 10; 26(26):4333-9. PMID: 18779620; PMCID: PMC2653118.
  147. Smith MR, Kyounghwa B, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU. Diabetes and mortality in men with locally advanced prostate cancer: analyses of RTOG 92-02. J Clin Oncol. 2008 May 20; 26(15_suppl):5013. PMID: 27948846.
    View in: PubMed
  148. Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1302-8. PMID: 18262732.
    View in: PubMed
  149. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008 Oct; 54(4):816-23. PMID: 18243498.
    View in: PubMed
  150. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007 Dec 15; 110(12):2691-9. PMID: 17999404; PMCID: PMC3047389.
  151. Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer. 2007 Apr 15; 109(8):1493-8. PMID: 17340594.
    View in: PubMed
  152. Efstathiou JA, Zietman AL, Kaufman DS, Heney NM, Coen JJ, Shipley WU. Bladder-sparing approaches to invasive disease. World J Urol. 2006 Nov; 24(5):517-29. PMID: 17082940.
    View in: PubMed
  153. Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug; 68(2):342-7. PMID: 16904449.
    View in: PubMed
  154. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, Taylor GA, Folkman J, D'Amato RJ. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril. 2005 Oct; 84 Suppl 2:1144-55. PMID: 16210006.
    View in: PubMed
  155. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J, D'Amato RJ, Rupnick MA. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril. 2005 Jan; 83(1):171-81. PMID: 15652904.
    View in: PubMed
  156. Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg. 2003 Apr; 237(4):530-5. PMID: 12677150; PMCID: PMC1514466.
  157. Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut. 2001 Mar; 48(3):367-71. PMID: 11171827; PMCID: PMC1760130.
  158. Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J, Frayling I, Efstathiou J, Pack K, Payne S, Roylance R, Gorman P, Sheer D, Neale K, Phillips R, Talbot I, Bodmer W, Tomlinson I. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med. 1999 Sep; 5(9):1071-5. PMID: 10470088.
    View in: PubMed
  159. Ilyas M, Efstathiou JA, Straub J, Kim HC, Bodmer WF. Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):3087-91. PMID: 10077641; PMCID: PMC15899.
  160. Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, Karayiannakis AJ, Mortensen NJ, Kmiot W, Playford RJ, Pignatelli M, Bodmer WF. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci U S A. 1999 Mar 02; 96(5):2316-21. PMID: 10051639; PMCID: PMC26781.
  161. Efstathiou JA, Pignatelli M. Modulation of epithelial cell adhesion in gastrointestinal homeostasis. Am J Pathol. 1998 Aug; 153(2):341-7. PMID: 9708793; PMCID: PMC1852965.
  162. Karayiannakis AJ, Syrigos KN, Efstathiou J, Valizadeh A, Noda M, Playford RJ, Kmiot W, Pignatelli M. Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. J Pathol. 1998 Aug; 185(4):413-8. PMID: 9828841.
    View in: PubMed
  163. Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3122-7. PMID: 9501226; PMCID: PMC19705.
  164. Luque EA, Tang LH, Bortecen KH, Kidd M, Miu K, Efstathiou JA, Modlin IM. Gastrin-regulated expression of p53 in transformed enterochromaffin-like cells in the African rodent mastomys. J Clin Gastroenterol. 1998; 27 Suppl 1:S116-24. PMID: 9872508.
    View in: PubMed
  165. Tang LH, Luque EA, Efstathiou JA, Bortecen KH, Kidd M, Tarasova NI, Modlin IM. Gastrin receptor expression and function during rapid transformation of the enterochromaffin-like cells in an African rodent. Regul Pept. 1997 Sep 26; 72(1):9-18. PMID: 9404728.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Efstathiou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_